Editorial Commentary
The evolving treatment paradigm for BRAF V600 mutant colorectal cancer
Abstract
Metastatic colorectal cancer (CRC) is now being better understood as a collection of diseases with each distinguished by distinct molecular profiles. BRAF mutant cancers are an important CRC subtype composing about 10% of metastatic CRCs. Of those with a mutation in the BRAF gene, 80% possess the V600E mutation (1).
